A Study Evaluating Safety and Therapeutic Activity of THOR-707 in Adult Subjects With Advanced or Metastatic Solid Tumors (THOR-707-101)

About the trial

Sponsor

Synthorx, Inc, a Sanofi company

Tested

THOR-707 (drug), Checkpoint inhibitor (drug), anti-EGFR antibody (drug)

Dates

Started 2019-06-20; completion 2025-12-02

Results posted

Not yet

Primary Objectives: * Evaluate the safety and tolerability of THOR-707 as a single agent and as a combination therapy (identify Dose Limiting Toxcitiy (DLTs) in Cohorts A, B, C, D, and G, and adverse events (AEs)/serious adverse event (SAE) profile in Cohorts A, B, C, D, E, F, and G) * Define the Maximium Tolerated Dose (MTD) and/or the Recommended Phase 2 Dose (RP2D) of THOR-707 as a single agent and as a combination therapy (Cohorts A, B, C, D, and G) * Evaluate preliminary anti-tumor activity of THOR-707 as a single agent by determination of the objective response rate (ORR) defined according to the Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (Cohort H only) Secon…

From ClinicalTrials.gov, last updated 2025-12-15. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Sanofi US Services Inc. reported $327,689 in research payments for this study in 2025 (118 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.